| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
|
Medicine details |
|
| Medicine name | tofacitinib (Xeljanz®) |
| Formulation | 5 mg film-coated tablet |
| Reference number | 936 |
| Indication | In combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs; as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/05/2017 |
| NICE guidance | TA480: Tofacitinib for moderate to severe rheumatoid arthritis |